We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Medical Marijuana Use in HIV+ Patients Prospective Cohort Study (MMC-1)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01536899
First Posted: February 22, 2012
Last Update Posted: October 26, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
Mark Greenwald, PhD, Wayne State University
February 16, 2012
February 22, 2012
October 26, 2017
February 2012
June 2017   (Final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT01536899 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Medical Marijuana Use in HIV+ Patients Prospective Cohort Study
Behavioral Economic Analysis of Medical Marijuana Use in HIV+ Patients Prospective Cohort Study

The investigators are interested in understanding personal factors such as medical conditions and mental health, as well as social and economic factors, that influence marijuana (and other substance) use in HIV-positive patients.

Several alternative hypotheses will be evaluated in the proposed project:

  1. healthier patients may self-select marijuana use;
  2. marijuana use may be associated with consequences that create barriers to seeking healthcare;
  3. marijuana use may have medicinal value that reduces the need for such care.

The study will involve a total of 5 interviews with clinical research staff members, the total involvement will be for about 1 year.

The first interview will establish a baseline of current behaviors and health status; this will take about 3-4 hours. This interview will take place at the Tolan Park Medical Building, located at 3901 Chrysler Service Dr. The remaining 4 interviews - which will be shorter in length - will be conducted about 3, 6, 9, and 12 months after the baseline interview; each follow-up interview will take about 2 hours.The purpose of the 4 remaining interviews is to assess changes in behaviors and health status over time.

We will collect urine samples at each of the 5 interview sessions to assess health and illicit drug use.

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
HIV positive and marijuana using volunteers
  • HIV Positive
  • Marijuana Smoking
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
150
June 2017
June 2017   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Participants will be patients in the HIV clinic.
  • Participants will have HIV.
  • Participants will sign a single consent form.
  • Participants will be marijuana users.

Exclusion Criteria:

  • Participants who test negative for marijuana will be excluded.
  • Volunteers who exhibit signs of drug intoxication or cognitive/mental impairment during the consent process will be excluded.
Sexes Eligible for Study: All
18 Years to 70 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01536899
MMC-1
R01DA032678 ( U.S. NIH Grant/Contract )
No
Not Provided
Not Provided
Mark Greenwald, PhD, Wayne State University
Wayne State University
National Institute on Drug Abuse (NIDA)
Principal Investigator: Mark Greenwald, PhD Wayne State University
Wayne State University
October 2017